What Fresenius Kabi’s PB016 regulatory filings mean for the Entyvio biosimilar market
Fresenius advances PB016 into FDA and EMA review, but competition, manufacturing scrutiny and IV-only positioning will shape its launch path.
Pharma & Biotech